Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare, Inc. (ALHC) reported that EVP, Corporate Affairs Joseph S. Konowiecki, a director and officer, sold 23,511 shares of common stock on September 17, 2026 at a weighted-average price of $8.61 per share. According to the disclosure, the sale was made to cover tax withholding obligations arising from the vesting of restricted stock units and is described as not a discretionary trade. Following this transaction, Konowiecki directly holds 1,080,305 shares of Alignment Healthcare common stock.
Alignment Healthcare, Inc. (ALHC) reported that Chief Executive Officer and director John E. Kao sold 27,400 shares of common stock on September 14, 2026 at $13.00 per share, in a sale described as a Rule 10b5-1 plan transaction and executed through an indirect holding.
The sold shares were held by the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee; following this transaction, that trust held 590,766 shares indirectly. Separately, Mr. Kao also reported a direct holding of 1,223,473 shares of Alignment Healthcare common stock as of the same date.
Alignment Healthcare, Inc. (ALHC) received a Rule 144 notice from director and EVP, Corporate Affairs Joseph Konowiecki covering a proposed sale of 26,000 shares of common stock through E-Trade, with an aggregate market value of $226,460, and an approximate sale date of September 17, 2026 on the Nasdaq Stock Market.
The shares relate to common stock acquired upon vesting of restricted stock units granted on September 14, 2023 under the company’s 2021 Equity Incentive Plan, with 43,554 shares acquired on that date. The notice states the transaction is a sale-to-cover for tax withholding and not a discretionary trade. It also lists prior three-month sales under a 10b5-1 sales plan totaling 75,000 shares for approximately $1.73 million.
Alignment Healthcare, Inc. (ALHC) reported that President Dawn Christine Maroney sold 122,707 shares of common stock on September 11, 2026. The shares were sold at a weighted-average price of $12.68 per share in multiple trades between $12.394 and $13.17 to cover tax withholding obligations arising from the vesting of restricted stock units, and the company notes this was not a discretionary trade. Following these sales, Maroney directly holds 794,606 shares of Alignment Healthcare common stock.
Alignment Healthcare, Inc. (ALHC) reported that Chief Executive Officer and director John E. Kao disclosed two sales of common stock totaling 557,870 shares.
On September 11, 2026, Kao sold 385,270 shares at a weighted-average price of $12.68 per share, in multiple trades between $12.394 and $13.17, to cover tax withholding obligations arising from the vesting of restricted stock units; the filing states this was not a discretionary trade. After this sale, he held 1,223,473 shares directly.
On September 10, 2026, a trust associated with Kao, the JEK Trust dated February 8, 2021, sold 172,600 shares at a weighted-average price of $12.96 per share, in trades between $12.71 and $13.21, under a Rule 10b5-1 trading plan adopted on May 27, 2026. These shares are reported as held indirectly, with 618,166 shares remaining in the trust after the transaction.
Alignment Healthcare, Inc. (ALHC) is the issuer of common stock covered by this notice, which states that JEK TRUST U/A DTD 02/08/2021 plans to sell 500,000 shares of ALHC common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares were originally issued pre-IPO in exchange for partnership units.
Alignment Healthcare, Inc. (ALHC) received a Rule 144 notice from President Dawn C. Maroney covering a proposed sale of 130,000 shares of common stock through E-Trade, with an indicated aggregate market value of $1,697,800 and 207,435,149 shares of common stock outstanding. The shares to be sold were acquired through the vesting of restricted stock units granted on September 12, 2022 under the company’s 2021 Equity Incentive Plan, and the filing notes the transaction is a sale-to-cover for tax withholding rather than a discretionary trade.
Alignment Healthcare, Inc. (ALHC) disclosed a planned sale of up to 405,000 shares of common stock under Rule 144 for the account of Chief Executive Officer and Director John Kao. The shares relate to equity awards, including 819,513 shares acquired through vesting of restricted stock units on September 12, 2022 under the company’s 2021 Equity Incentive Plan.
The notice states that the transaction is a sale-to-cover for tax withholding and does not represent a discretionary trade by John Kao; the actual number of shares sold will depend on applicable tax withholding rates and the stock price at the time of sale. In the prior three months, entities under a 10b5-1 Sales Plan associated with Kao reported three sales of 298,000 shares each.
Alignment Healthcare, Inc. (ALHC) reported an insider transaction by President Dawn Christine Maroney. On 2026-08-14, she sold 5,000 shares of common stock at $14.00 per share in an open-market or private transaction. After this sale, she directly held 917,313 shares of Alignment Healthcare common stock. The transaction was carried out under a Rule 10b5-1 trading plan adopted on 2026-03-13.
A shareholder associated with ALHC filed a Rule 144 notice indicating an intention to sell 5,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $67,300. These shares relate to RSU/PSU awards dated September 25, 2020.
Within the past three months, the same filer executed 10b5-1 plan sales of common stock totaling 237,068 shares, including 177,068 shares for $3,687,990.22 on July 15, 2026, and two 30,000‑share sales for $586,424.50 and $482,567.00.